Small study links estriol regimen to less menopause brain fog

The number is small but easy to remember: 20 menopausal women took part in a UCLA Health observational case series. After a baseline assessment, they received a customized combination of estriol and progesterone for 12 months. At the end, participants reported less brain fog and fewer problems with concentration, working memory, processing speed, verbal memory and problem-solving.

The researchers are not presenting estriol as a proven cognitive treatment. The study had no placebo group and no randomization, so changes could reflect factors other than the hormone regimen and may not apply to a broader population. The reported gains are signals that need testing in larger, placebo-controlled clinical trials with brain imaging and standardized cognitive assessments.

Estriol is a natural form of estrogen associated with pregnancy. It differs from estradiol, the estrogen most commonly used in hormone therapy in the United States, by binding primarily to a different estrogen receptor in the brain. Earlier research cited by the team suggests estriol may help protect brain cells and reduce atrophy in the hippocampus, the region involved in learning and memory. In complementary experiments, midlife female mice given estriol showed fewer markers of hippocampal pathology and better working and spatial memory.

The treatment also has a direct commercial connection to the research. Dr. Rhonda Voskuhl, the study's senior author and a UCLA neurologist, invented the regimen. UCLA holds the patent and licenses it to CleopatraRX, which sells it under the name PearlPAK; Voskuhl serves as the company's medical advisor. That relationship makes independent replication especially relevant.

So what changes in practice? For women whose menopause-related cognitive symptoms are dismissed as something to tolerate, the study points to a testable treatment hypothesis rather than an established option. Estriol has been used in Europe and Asia for hot flashes and genitourinary symptoms, but this study does not establish a dose or prove effectiveness for brain fog. The next step is clinical trials that can show whether the reported benefits hold beyond this small group.